Could a Pre-IVF pill boost baby chances for endometriosis patients?
NCT ID NCT06375811
First seen Jun 06, 2026 · Last updated Jun 23, 2026 · Updated 4 times
Summary
This Phase 3 trial tests whether taking Elagolix, a hormone-blocking drug, before IVF can increase live birth rates in women with endometriosis. About 97 women will receive either Elagolix or a placebo before their IVF cycle. The goal is to see if this pre-treatment improves the chance of having a baby.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ENDOMETRIOSIS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Duke Fertility
Morrisville, North Carolina, 27560, United States
-
Johns Hopkins, Division of Reproductive Science and Women's Health Research
Baltimore, Maryland, 21205, United States
-
Northwestern University Department of Obstetrics and Gynecology
Chicago, Illinois, 60611, United States
-
University of Colorado Department of Obstetrics & Gynecology
Aurora, Colorado, 80045, United States
-
Yale School of Medicine Dept.of Ob/Gyn & Reproductive Sciences
New Haven, Connecticut, 06520, United States
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Elagolix (Orlissa)
What this could lead to
If successful, this could offer a new pre-treatment option to improve IVF success rates for women with endometriosis.
What could go wrong
This is a Phase 3 trial, but results are not yet available. The benefit may be modest or not apply to all women with endometriosis.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.